Show simple item record

dc.contributor.authorFridman, Vera
dc.contributor.authorSuriyanarayanan, Saranya
dc.contributor.authorNovak, Peter
dc.contributor.authorDavid, William
dc.contributor.authorMacklin, Eric A.
dc.contributor.authorMcKenna-Yasek, Diane
dc.contributor.authorWalsh, Kailey
dc.contributor.authorAziz-Bose, Razina
dc.contributor.authorOaklander, Anne Louise
dc.contributor.authorBrown, Robert H. Jr.
dc.contributor.authorHornemann, Thorsten
dc.contributor.authorEichler, Florian
dc.date2022-08-11T08:09:52.000
dc.date.accessioned2022-08-23T16:46:36Z
dc.date.available2022-08-23T16:46:36Z
dc.date.issued2019-01-22
dc.date.submitted2019-02-28
dc.identifier.citation<p>Neurology. 2019 Jan 22;92(4):e359-e370. doi: 10.1212/WNL.0000000000006811. Epub 2019 Jan 9. <a href="https://doi.org/10.1212/WNL.0000000000006811">Link to article on publisher's site</a></p>
dc.identifier.issn0028-3878 (Linking)
dc.identifier.doi10.1212/WNL.0000000000006811
dc.identifier.pmid30626650
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40914
dc.description.abstractOBJECTIVE: To evaluate the safety and efficacy of l-serine in humans with hereditary sensory autonomic neuropathy type I (HSAN1). METHODS: In this randomized, placebo-controlled, parallel-group trial with open-label extension, patients aged 18-70 years with symptomatic HSAN1 were randomized to l-serine (400 mg/kg/day) or placebo for 1 year. All participants received l-serine during the second year. The primary outcome measure was the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS). Secondary outcomes included plasma sphingolipid levels, epidermal nerve fiber density, electrophysiologic measurements, patient-reported measures, and adverse events. RESULTS: Between August 2013 and April 2014, we enrolled and randomized 18 participants, 16 of whom completed the study. After 1 year, the l-serine group experienced improvement in CMTNS relative to the placebo group (-1.5 units, 95% CI -2.8 to -0.1, p = 0.03), with evidence of continued improvement in the second year of treatment (-0.77, 95% CI -1.67 to 0.13, p = 0.09). Concomitantly, deoxysphinganine levels dropped in l-serine-treated but not placebo-treated participants (59% decrease vs 11% increase; p < 0.001). There were no serious adverse effects related to l-serine. CONCLUSION: High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression. CLINICALTRIALSGOV IDENTIFIER: NCT01733407. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that high-dose oral l-serine supplementation significantly slows disease progression in patients with HSAN1.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30626650&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2019 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectL-serine
dc.subjecthereditary sensory autonomic neuropathy type I
dc.subjectHSAN1
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectCongenital, Hereditary, and Neonatal Diseases and Abnormalities
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.subjectTherapeutics
dc.titleRandomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1
dc.typeJournal Article
dc.source.journaltitleNeurology
dc.source.volume92
dc.source.issue4
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4726&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3714
dc.identifier.contextkey13921316
refterms.dateFOA2022-08-23T16:46:36Z
html.description.abstract<p>OBJECTIVE: To evaluate the safety and efficacy of l-serine in humans with hereditary sensory autonomic neuropathy type I (HSAN1).</p> <p>METHODS: In this randomized, placebo-controlled, parallel-group trial with open-label extension, patients aged 18-70 years with symptomatic HSAN1 were randomized to l-serine (400 mg/kg/day) or placebo for 1 year. All participants received l-serine during the second year. The primary outcome measure was the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS). Secondary outcomes included plasma sphingolipid levels, epidermal nerve fiber density, electrophysiologic measurements, patient-reported measures, and adverse events.</p> <p>RESULTS: Between August 2013 and April 2014, we enrolled and randomized 18 participants, 16 of whom completed the study. After 1 year, the l-serine group experienced improvement in CMTNS relative to the placebo group (-1.5 units, 95% CI -2.8 to -0.1, p = 0.03), with evidence of continued improvement in the second year of treatment (-0.77, 95% CI -1.67 to 0.13, p = 0.09). Concomitantly, deoxysphinganine levels dropped in l-serine-treated but not placebo-treated participants (59% decrease vs 11% increase; p < 0.001). There were no serious adverse effects related to l-serine.</p> <p>CONCLUSION: High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression.</p> <p>CLINICALTRIALSGOV IDENTIFIER: NCT01733407.</p> <p>CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that high-dose oral l-serine supplementation significantly slows disease progression in patients with HSAN1.</p>
dc.identifier.submissionpathoapubs/3714
dc.contributor.departmentDepartment of Neurology
dc.source.pagese359-e370


Files in this item

Thumbnail
Name:
e359.full.pdf
Size:
754.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2019 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Except where otherwise noted, this item's license is described as Copyright © 2019 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.